Background: Hepatitis B virus (HBV) infection remains a global health problem. As
“cure” for chronic hepatitis B is of current priority, hepatitis B immunoglobulin (HBIG) has been utilized
for several decades to provide post-exposure prophylaxis.
In recent years, a number of monoclonal antibodies (mAbs) targeting HBV have been developed and
demonstrated with high affinity, specificity, and neutralizing potency.
Objective: HBV neutralizing antibodies may play a potentially significant role in the search for an
HBV cure. In this review, we will summarize the recent progress in developing HBV-neutralizing
antibodies, describing their characteristics and potential clinical applications.
Results and Conclusion: HBV neutralizing antibodies could be a promising alternative in the prevention
and treatment of HBV infection. More importantly, global collaboration and coordinated approaches
are thus needed to facilitate the development of novel therapies for HBV infection.